Global Human Rho(D) Immune Globulin Market Growth 2025-2031
Description
The global Human Rho(D) Immune Globulin market size is predicted to grow from US$ 45.4 million in 2025 to US$ 69.5 million in 2031; it is expected to grow at a CAGR of 7.4% from 2025 to 2031.
Rho(D) immune globulin (RhIG) is a medication used to prevent Rh isoimmunization in mothers who are Rh negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. It is often given both during and following pregnancy. It may also be used when Rh negative people are given Rh positive blood. It is given by injection into muscle or a vein. A single dose lasts 2 to 4 weeks.
United States market for Human Rho(D) Immune Globulin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Human Rho(D) Immune Globulin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Human Rho(D) Immune Globulin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Human Rho(D) Immune Globulin players cover СЅL Веhrіng, Grіfоlѕ, Bayer, Kedrion Biopharma, Saol Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Human Rho(D) Immune Globulin Industry Forecast” looks at past sales and reviews total world Human Rho(D) Immune Globulin sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Rho(D) Immune Globulin sales for 2025 through 2031. With Human Rho(D) Immune Globulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Rho(D) Immune Globulin industry.
This Insight Report provides a comprehensive analysis of the global Human Rho(D) Immune Globulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Rho(D) Immune Globulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Rho(D) Immune Globulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Rho(D) Immune Globulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Rho(D) Immune Globulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Rho(D) Immune Globulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vial
Prefilled Syringe
Segmentation by Application:
Government Institution
Private Sector
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
СЅL Веhrіng
Grіfоlѕ
Bayer
Kedrion Biopharma
Saol Therapeutics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Rho(D) Immune Globulin market?
What factors are driving Human Rho(D) Immune Globulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Rho(D) Immune Globulin market opportunities vary by end market size?
How does Human Rho(D) Immune Globulin break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Rho(D) immune globulin (RhIG) is a medication used to prevent Rh isoimmunization in mothers who are Rh negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. It is often given both during and following pregnancy. It may also be used when Rh negative people are given Rh positive blood. It is given by injection into muscle or a vein. A single dose lasts 2 to 4 weeks.
United States market for Human Rho(D) Immune Globulin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Human Rho(D) Immune Globulin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Human Rho(D) Immune Globulin is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Human Rho(D) Immune Globulin players cover СЅL Веhrіng, Grіfоlѕ, Bayer, Kedrion Biopharma, Saol Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Human Rho(D) Immune Globulin Industry Forecast” looks at past sales and reviews total world Human Rho(D) Immune Globulin sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Rho(D) Immune Globulin sales for 2025 through 2031. With Human Rho(D) Immune Globulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Rho(D) Immune Globulin industry.
This Insight Report provides a comprehensive analysis of the global Human Rho(D) Immune Globulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Rho(D) Immune Globulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Rho(D) Immune Globulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Rho(D) Immune Globulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Rho(D) Immune Globulin.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Rho(D) Immune Globulin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vial
Prefilled Syringe
Segmentation by Application:
Government Institution
Private Sector
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
СЅL Веhrіng
Grіfоlѕ
Bayer
Kedrion Biopharma
Saol Therapeutics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Rho(D) Immune Globulin market?
What factors are driving Human Rho(D) Immune Globulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Rho(D) Immune Globulin market opportunities vary by end market size?
How does Human Rho(D) Immune Globulin break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
81 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Human Rho(D) Immune Globulin by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Human Rho(D) Immune Globulin by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
